Bio Pharma Dive
NOVEMBER 9, 2021
Encouraged by Moderna's success, Flagship Pioneering has been busy creating startups like Alltrna, which launched Tuesday. The biotech is researching how to make medicines from transfer RNA molecules.
World of DTC Marketing
NOVEMBER 9, 2021
SUMMARY: Quantitative and qualitative data was gained through surveys with EPG Health’s multi-stakeholder databases (HCP, pharma, and service providers) and interviews conducted with pharma execs by Impatient Health. The objective was to identify new and preferred pathways for the creation and delivery of medical information. Key Findings 1 : HCPS ARE IN CONTROL AND PHARMA KNOWS IT.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
JAMA Internal Medicine
NOVEMBER 7, 2021
This cross-sectional study of individuals from the French CONSTANCES cohort assesses whether the belief in having been infected with SARS-CoV-2, having serological test–confirmed COVID-19 infection, or both are associated with persistent physical symptoms often attributed to long COVID in the general adult population.
Pharma Times
NOVEMBER 11, 2021
ChAdOxl biEBOV is being tested for safety and immunogenicity, and may protect against multiple species of the virus
Bio Pharma Dive
NOVEMBER 8, 2021
Study results for Mirati's drug combined with Keytruda have been much anticipated, as the San Diego biotech aims to challenge Amgen and its rival KRAS-blocking drug Lumakras.
pharmaphorum
NOVEMBER 12, 2021
Researchers in the US have developed an artificial intelligence-based tool that is able to predict COVID-19 symptoms and suggest which FDA-approved drugs might be used to treat patients. The MOATAI-VIR algorithm, developed by scientists at Emory University and Georgia Tech, was put through its paces in a study that showed it was able to predict 24 out of 26 clinical manifestations of COVID-19, including acute respiratory distress, blood clotting issues, cytokine storms, brain fog, and loss of sm
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
NOVEMBER 12, 2021
Researchers have said that next generation vaccines for COVID-19 should aim to induce a response against ‘replication proteins’
Bio Pharma Dive
NOVEMBER 12, 2021
The industry giant and mainstay of corporate America will separate its consumer health business from its drug and medical device units, which will retain the J&J brand.
BioPharma Reporter
NOVEMBER 9, 2021
Dutch stem cell company Neuroplast has announced positive Phase 1 results for its Neuro-Cells investigational stem cell treatment in patients suffering from Traumatic Spinal Cord Injury (TSCI).
pharmaphorum
NOVEMBER 8, 2021
The UK government has announced £248 million in spending over the next year for a project to make it easier for patient test results and scans to be shared between hospitals, labs and GP surgeries. The aim is to “digitise diagnostics care” across the NHS, reducing the time it takes to diagnose health problems and get treatment started earlier, helping to address the massive backlog in care caused by the pandemic, according to a Department of Health and Social Care (DHSC) statement.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
NOVEMBER 7, 2021
Researchers aren’t sure why the mRNA vaccines appear to, in rare cases, cause heart inflammation. The FDA said the risk appears higher within seven days of the second jab of the vaccines.
Bio Pharma Dive
NOVEMBER 12, 2021
Detailed results presented Thursday show no difference between the biotech's drug and placebo on the study's main measures. But a seeming benefit in a subgroup of patients convinced the company to plan another trial.
XTalks
NOVEMBER 10, 2021
More and more, we’re hearing the term “vertical farming” being used, and the idea is becoming increasingly popular. The increase in population and shift of communities moving from rural to urban areas has allowed indoor and vertical farming to take off. Additionally, advancements in lighting, such as light-emitting diode (LED) technologies, the conveniences of agriculture within the city, advanced architecture and more are making all of this possible.
pharmaphorum
NOVEMBER 9, 2021
Scotland has given the green light to AstraZeneca’s Tagrisso for restricted use to treat adult patients with non-small cell lung cancer (NSCLC), making it the first country in the world to approve the routine use of the therapy in this setting. The Scottish Medicines Consortium (SMC) has approved Tagrisso (osimertinib) for use within NHS Scotland as a monotherapy for adjuvant treatment after tumour removal in adult patients with stage IB-IIIA NSCLC whose tumours have epidermal growth factor (EGF
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharma Times
NOVEMBER 10, 2021
Janssen's Ponvory accepted for use within NHS Scotland for adults RRMS patients
Bio Pharma Dive
NOVEMBER 11, 2021
Data presented at an Alzheimer's meeting raised more questions about the seeming benefit of Roche and AC Immune's drug semorinemab, which they claim is the first of its kind to slow deterioration of memory.
XTalks
NOVEMBER 10, 2021
As big food brands shift towards ecommerce and direct-to-consumer (DTC) sales, there has been a notable uptick in their efforts to gain access to first-party consumer data. Whether it’s through personalized offerings or limited-edition products, many big food brands are employing marketing tactics to gain valuable data from consumers. First and foremost, the tactics are used to sell product — and clearly, they are working.
pharmaphorum
NOVEMBER 10, 2021
Tackling antimicrobial resistance (AMR) requires a one health approach that joins the dots between the human, animal, and environmental drivers, consequences, and data. AMR threatens to undermine “almost a century of health gains” and marshalling a response to such a problem “requires cooperation at many levels”. That’s according to a newly published report from the US National Academies of Sciences, Engineering, and Medicine, which calls for a One Health approach that recognises the scale of th
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
BioSpace
NOVEMBER 8, 2021
Research into Alzheimer’s disease is shifting from amyloid plaque and tau protein to neuroinflammation, white matter changes and insulin resistance.
Bio Pharma Dive
NOVEMBER 11, 2021
The biotech claimed its NIH partners were involved only after a key discovery was made "by Moderna scientists using Moderna technology." The dispute could end up in court.
Pharma Times
NOVEMBER 8, 2021
Daprodustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor in development for anaemia due to chronic kidney disease
pharmaphorum
NOVEMBER 11, 2021
Shares in France’s Valneva leaped after it got an EU order to supply 60 million doses of its COVID-19 vaccine VLA2001 over the next two years, including 27 million next year. The deal for the adjuvanted, inactivated SARS-CoV-2 vaccine still depends on authorisation of the jab by the European Medicines Agency (EMA) which is due to start a rolling review of VLA2001 shortly, but Valneva thinks it could start delivering supplies to the EU in April next year.
Scienmag
NOVEMBER 12, 2021
Carbon is the building block of all known life on our planet. The carbon cycle regulates the release and absorption of carbon from a number of natural sources — including the ocean, soil, geochemical processes, and human emissions — to maintain a delicate balance of this crucial element in our world. Credit: Kristin Rose Jutras […].
Bio Pharma Dive
NOVEMBER 8, 2021
Shortly after postponing a $135 million IPO, Gyroscope has found another way to back a treatment for a disease that's become a top target of multiple drugmakers.
Pharma Times
NOVEMBER 9, 2021
iiCON’s lead partner LSTM will independently validate CN Bio’s novel lung and lung-liver models
pharmaphorum
NOVEMBER 10, 2021
After being hailed as a triumph of public-private drug development, Moderna’s partnership with the US government on its COVID-19 vaccine looks like it may descend into acrimony. That is according to a New York Times report , which says Moderna is now in dispute with the National Institutes of Health (NIH) after it filed a US patent in the US that claims the company’s scientists invented the vaccine on their own.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
XTalks
NOVEMBER 11, 2021
The US National Institutes of Health (NIH) and Moderna continue to be at loggerheads in a COVID-19 vaccine patent spat, with the federal health agency not ruling out legal action against the Cambridge, Massachusetts-based biotech. The NIH says their scientists played “a major role” in developing Moderna’s COVID-19 vaccine and, hence, plans to defend its claim of co-ownership, NIH Director Dr.
Bio Pharma Dive
NOVEMBER 9, 2021
The new agreement raises the financial upside of molnupiravir, which Merck believes could be a $7 billion product in 2022. But Pfizer's rival drug, which has produced seemingly superior efficacy, could affect those projections.
Pharma Times
NOVEMBER 9, 2021
Funding proceeds will be used to support ongoing trials of Gyroscopes investigational gene therapy GT005
pharmaphorum
NOVEMBER 10, 2021
Germany’s vaccination advisory committee has recommended that people aged under 30 should only be offered Pfizer/BioNTech’s COVID-19 vaccine Comirnaty, saying it seems less likely to cause heart inflammation than Moderna’s rival shot Spikevax. The draft guidance from the Robert Koch Institute’s STIKO committee also says that pregnant women, regardless of their age, should get the Pfizer/BioNTech vaccine.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
359 
Let's personalize your content